Stockreport

Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed [Seeking Alpha]

VIVUS  (VVUS) 
Last vivus earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vivus.com/node/5806
PDF Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena FailedSummaryNovo Nordisk's injectable semaglutide succeeded in Phase II trials for weight loss, and [Read more]